Literature DB >> 19094830

Allodynia as a complication of migraine: background and management.

William B Young1.   

Abstract

Allodynia is a normal part of the untreated migraine attack in most people with episodic migraine and is prevalent in chronic migraine. The extent to which allo-dynia contributes to the pain and disability of migraine attacks is unclear, as is its clinical importance. The presence of allodynia correlates with the severity and other features of migraine, including aura, migraine-associated symptoms, and motor symptoms. The development of allodynia is associated with resistance to triptan treatment. It is uncertain whether this treatment resistance is due to the accompanying increase in headache severity or whether the development of allo-dynia is the fundamental biologic event causing the new treatment-refractory state. Animal models support the relationship to allodynia. Intravenous ketorolac may be effective at treating migraine with allodynia several hours after the development of the throbbing pain, but prior treatment with opioid analgesics may confer treatment resistance. Occipital nerve blocks rapidly treat migraine pain and allodynia. Uncontrolled studies have successfully used dihydroergotamine to treat episodic and chronic migraine with allodynia.

Entities:  

Year:  2009        PMID: 19094830     DOI: 10.1007/s11940-009-0001-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  30 in total

1.  Observations on 500 cases of migraine and allied vascular headache.

Authors:  G SELBY; J W LANCE
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  Identifying cutaneous allodynia in chronic migraine using a practical clinical method.

Authors:  A Ashkenazi; M Sholtzow; J W Shaw; R Burstein; W B Young
Journal:  Cephalalgia       Date:  2007-02       Impact factor: 6.292

3.  Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons.

Authors:  R Burstein; H Yamamura; A Malick; A M Strassman
Journal:  J Neurophysiol       Date:  1998-02       Impact factor: 2.714

4.  The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine.

Authors:  R Burstein; M F Cutrer; D Yarnitsky
Journal:  Brain       Date:  2000-08       Impact factor: 13.501

5.  Migraine with unilateral motor symptoms: a case-control study.

Authors:  William B Young; Kaanchan S Gangal; Raoul J Aponte; Ronald S Kaiser
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

6.  Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.

Authors:  Stephen D Silberstein; William B Young; Mary M Hopkins; Cheryl Gebeline-Myers; Kathleen C Bradley
Journal:  Headache       Date:  2007-06       Impact factor: 5.887

7.  Prevalence and characteristics of allodynia in headache sufferers: a population study.

Authors:  M E Bigal; S Ashina; R Burstein; M L Reed; D Buse; D Serrano; R B Lipton
Journal:  Neurology       Date:  2008-04-22       Impact factor: 9.910

8.  The first 5 minutes after greater occipital nerve block.

Authors:  William Young; Brianna Cook; Shahram Malik; James Shaw; Michael Oshinsky
Journal:  Headache       Date:  2008-06-28       Impact factor: 5.887

9.  Clinical recognition of allodynia in migraine.

Authors:  Ninan T Mathew; Jayasree Kailasam; Tad Seifert
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

10.  Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.

Authors:  Ninan T Mathew; Jayasree Kailasam; Lori Meadors
Journal:  Headache       Date:  2007-09-12       Impact factor: 5.887

View more
  2 in total

1.  Ictal and interictal brain activation in episodic migraine: Neural basis for extent of allodynia.

Authors:  Nasim Maleki; Edina Szabo; Lino Becerra; Eric Moulton; Steven J Scrivani; Rami Burstein; David Borsook
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

2.  Gabapentin inhibits central sensitization during migraine.

Authors:  Yanbo Zhang; Guo Shao; Wei Zhang; Sijie Li; Jingzhong Niu; Dongmei Hu; Mingfeng Yang; Xunming Ji
Journal:  Neural Regen Res       Date:  2013-11-15       Impact factor: 5.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.